# A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

> **NCT03192111** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Renal Impairment
- Healthy Volunteer

## Interventions

- **DRUG:** Entinostat

## Key facts

- **NCT ID:** NCT03192111
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-27
- **Primary completion:** 2017-11-23
- **Final completion:** 2017-11-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192111, "A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03192111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*